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OBJECTIVES: POLARIS is a 26-week, double-blind, ran-
domised study comparing the efﬁcacy of rosuvastatin (RSV) 
40mg with atorvastatin (ATV) 80mg in high-risk patients
(known CHD or CHD-risk equivalent, as deﬁned by NCEP ATP
III) with hypercholesterolaemia. Using a secondary prevention
model, results from POLARIS were used to estimate longer-term
costs and beneﬁts. METHODS: Efﬁcacy data from POLARIS
(TC, HDL-C, and TG) were used as input to the model. Markov
models were run in 4-year cycles over 20 years, from age 55 to
76 years for men and women separately. Secondary CHD risk
was based on Framingham data (d’Agostino et al. AHJ 2000)
but calibrated to British Regional Heart Study (Brindle et al. BMJ
2003). Estimates for life expectancy, health-care costs and
quality-adjusted life years (QALYs) were assigned to patients as
they transitioned through the model. RESULTS: RSV 40mg
improved levels of TC and HDL-C more than ATV 80mg (-41%
vs. -39%; +11.0 vs. +6.2%, respectively).The model predicts
that more secondary CHD events and deaths are avoided 
with RSV 40mg compared with ATV 80mg in both high-risk
men and women; hence, more life-years and QALYs are gener-
ated and event costs are lower. More patients survive on treat-
ment and therefore total costs with RSV 40mg are slightly
higher. Cost per life year gained (men: £1113, women: £1065)
and QALY gained (men: £2091, women: £3079) are favourable
for RSV 40mg. CONCLUSIONS: RSV 40mg is likely to be more
effective both clinically and economically than ATV 80mg for
the secondary prevention of CHD.
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While treatment guidelines recommend lowering cholesterol to
target levels, many remain above goal (LDL-C >100mg/dL for
CHD/diabetic patients and LDL-C >130mg/dl for other non-
CHD high risk individuals). OBJECTIVE: To assess the change
in LDL-C and goal attainment rates due to switching patients to
an Ezetimibe/Simvastatin dose titration strategy, compared with
a simulated statin monotherapy dose titration strategy.
METHOD: A decision-analytic model was developed to project
goal attainment at end of 1-year after therapy change. Clinical
trial data were used to estimate LDL-C reductions for different
treatment strategies. The model was run for a population of 504
Spanish patients (237 CHD/diabetic and 267 non-CHD high risk
patients) that had not reached LDL-C goal levels 3-months after
starting statin therapy. Patients not at goal where up titrated (till
goal attainment or to the maximum dose whichever was ﬁrst)
every 3 months both in the Ezetimibe/Simvastatin (only simvas-
tatin titrated) and in the statin monotherapy titration arms.
RESULTS: Mean age was 60.8 (SD 9.8) years, 47.8% female,
lipid proﬁle (mg/dl) at three months on statin monotherapy was
LDL-C 182.3 (SD 35.1), TC 262.1 (SD 39.5), HDL-C 50.8 (SD
14.1), triglycerides 150.1 (SD 82.5). Ezetimibe/Simvastatin
therapy is projected to achieve a 82.6% goal attainment rate,
compared with 46.0% projected for the statin titration strategy.
With respect to LDL-C reductions, Ezetimibe/Simvastatin would
achieve a 38.2% reduction over baseline, compared with a
24.5% with the statin titration strategy. In the statin arm, 73.9%
of the patients reached the statin maximum dose, whereas in the
Ezetimibe/Simvastatin arm, only 23.5% of the patients did so.
CONCLUSION: Compared to statin monotherapy titration,
switching patients not at goal on statin monotherapy to Ezetim-
ibe/Simvastatin followed by titration is projected to get 36.6%
additional patients to goal and reduce LDL-c by 13.7%.
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OBJECTIVE: The objective of this study was to describe the
burden of modiﬁable risk factors and of the total CV risk in a
population, free of CVD, selected in general practice, on the basis
of age (40–75yrs) and waist circumference (>=94cm in men and
>=80cm in women). METHODS: In total, 619 Belgian GPs
recruited consecutive patients during spring 2004. A central lab
analysed fasting blood samples. RESULTS: Complete data on
8587 patients were obtained. Mean age was 58yrs (47%
women). Mean BMI and waist were 30.1kg/m2 and 99cm for
women and 30.1kg/m2 and 107cm for men. Eighteen-percent
had diabetes (D) either known and treated (14%) or newly
detected, based on fasting glucose levels (4%). Of the non-
diabetic subjects (ND), 25% had ° 3 metabolic syndrome risk
factors (NCEP-ATP III criteria). Twenty-four percent of the total
population was smoking and 84% did not engage in regular
physical activity. Seventy-seven percent of ND had LDL 
cholesterol >=115mg/dl & 78% of D had LDL cholesterol
>=100mg/dl. Only 31% of subjects on lipid lowering drugs had
TC < 190 and LDL <115mg/dl. 49% of ND had BP >=140/90
mmHg and 91% of the D had BP >=130/80mmHg. Total CV
risk in the ND was estimated using the SCORE chart calibrated
for Belgium. Total risk >=5% for dying from CVD in the coming
10yrs was present in more than 40% of men and in more than
20% of women. CONCLUSION: Waist measurement is an easy
and inexpensive tool to detect, in the middle-aged population
free of CVD, a subgroup with a large variety of modiﬁable risk
factors and at high risk for CV death. A large majority of them
is physically inactive, an unacceptable proportion is smoking and
both total cholesterol and blood pressure are insufﬁciently
managed.
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OBJECTIVES: The main aim is to evaluate the variability of
practitioners’ prescribing behaviour on statines in AUSL Bologna
South from 2000 to 2003, as well as to quantify how much such
a behaviour depends on culture, education and policy of practi-
tioner. METHODS: A multilevel model has been built to reﬂect
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